Download PDF
Thromb Haemost 2011; 106(06): 1226-1227
DOI: 10.1160/TH11-07-0462
Letters to the Editor
Schattauer GmbH

Repeated NT-proBNP testing and risk for adverse outcome after acute pulmonary embolism

Wendy Zondag   *
1   Section of Vascular Medicine, Department of Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands
,
Mariette J. Agterof   *
2   Van Creveldkliniek/Department of Hematology, University Medical Centre Utrecht, Utrecht, The Netherlands
,
Roger E. G. Schutgens
2   Van Creveldkliniek/Department of Hematology, University Medical Centre Utrecht, Utrecht, The Netherlands
,
Olaf M. Dekkers
3   Department of Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands
,
Douwe H. Biesma
2   Van Creveldkliniek/Department of Hematology, University Medical Centre Utrecht, Utrecht, The Netherlands
4   St. Antonius Hospital, Nieuwegein, The Netherlands
,
Menno V. Huisman
1   Section of Vascular Medicine, Department of Internal Medicine, Leiden University Medical Centre, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received: 07 July 2011

Accepted after major revision: 02 September 2011

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

 

* Both authors contributed equally.


 

  • References

  • 1 Klok FA, Mos IC, Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008; 178: 425-430.
    CrossrefPubMedGoogle Scholar
  • 2 ten Wolde M, Tulevski I I, Mulder JW. et al. Brain natriuretic peptide as a predictor of adverse outcome in patients with pulmonary embolism. Circulation 2003; 107: 2082-2084.
    CrossrefPubMedGoogle Scholar
  • 3 Kucher N, Printzen G, Doernhoefer et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003; 107: 1576-1578.
    CrossrefPubMedGoogle Scholar
  • 4 Kostrubiec M, Pruszczyk P, Bochowicz A. et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J 2005; 26: 2166-2172.
    CrossrefPubMedGoogle Scholar
  • 5 Vuilleumier N, Perrier A, Sanchez JC. et al. Cardiac biomarkers levels predict pulmonary embolism extent on chest computed tomography and prognosis in non-massive pulmonary embolism. Thromb Haemost 2009; 101: 1176-1178.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Becattini C, Agnelli G. Predictors of mortality from pulmonary embolism and their influence on clinical management. Thromb Haemost 2008; 100: 747-751.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Agterof MJ, Schutgens RE, Snijder RJ. et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT-proBNP level. J Thromb Haemost 2010; 8: 1235-1241.
    CrossrefPubMedGoogle Scholar
  • 8 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454S-545S.
    CrossrefPubMedGoogle Scholar
  • 9 Kostrubiec M, Pruszczyk P, Kaczynska A. et al. Persistent NT-proBNP elevation in acute pulmonary embolism predicts early death. Clin Chim Acta 2007; 382: 124-128.
    CrossrefPubMedGoogle Scholar